|1.||Lew, Mark F: 4 articles (09/2012 - 11/2002)|
|2.||Brashear, A: 4 articles (12/2006 - 01/2000)|
|3.||Dressler, Dirk: 4 articles (12/2005 - 12/2002)|
|4.||Zhang, Yuxin: 3 articles (09/2012 - 04/2010)|
|5.||Chinnapongse, Robert: 3 articles (02/2012 - 04/2010)|
|6.||Pappert, Eric J: 3 articles (11/2010 - 07/2007)|
|7.||Bayes, M: 3 articles (09/2006 - 05/2005)|
|8.||Prous, J R: 3 articles (09/2006 - 05/2005)|
|9.||Rabasseda, X: 3 articles (09/2006 - 05/2005)|
|10.||Dressler, D: 3 articles (04/2006 - 02/2002)|
02/01/2005 - "Short-term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long-term studies have been published and the safety and efficacy of higher doses has not been established. "
09/01/2005 - "Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A-resistant (AR) and non-A-resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. "
01/01/2000 - "The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials."
09/01/2012 - "Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials."
11/01/2010 - "Evaluate the safety and efficacy of a sequential dose escalation of rimabotulinumtoxinB (BoNT-B) in cervical dystonia (CD) subjects. "
03/01/2005 - "Recently, botulinum toxin type B has been shown to be effective in the treatment of drooling. "
01/01/2010 - "Like for PD, botulinum toxin type B represents an effective and safe treatment for neuroleptic-induced sialorrhea with a treatment effect of 8 to 16 weeks."
02/01/2009 - "Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. "
12/01/2012 - "Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion."
02/01/2012 - "We conclude that intraglandular injection of botulinum toxin type B was safe, tolerable, and efficacious in treating sialorrhea in PD patients. "
03/01/2005 - "Neurobloc is an effective treatment for axillary hyperhidrosis."
03/01/2005 - "Myobloc proved to be efficacious for the treatment of palmar hyperhidrosis. "
07/01/2014 - "Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study."
03/01/2005 - "We evaluated the safety and efficacy of Myobloc in the treatment of bilateral palmar hyperhidrosis. "
03/01/2005 - "To investigate the efficacy of Neurobloc for axillary hyperhidrosis. "
09/01/2015 - "Lumbar Sympathetic Block with Botulinum Toxin Type B for Complex Regional Pain Syndrome: A Case Study."
07/01/2015 - "Botulinum toxin type B for chronic pain: panacea or snake oil? "
12/01/2014 - "Botulinum toxin type B: pH change reduces injection pain, retains efficacy."
04/01/2012 - "[Effect of botulinum toxin type B on residual limb sweating and pain. "
06/01/2003 - "Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial."
|5.||Dysphonia (Spastic Dysphonia)
02/01/2005 - "[The dosage of botulinum toxin type B in adductor type spasmodic dysphonia]."
09/01/2002 - "Botulinum toxin type B for treatment of spasmodic dysphonia: a case report."
09/01/2002 - "Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. "
09/01/2004 - "This single-site, open-label, dose-finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT-B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. "
09/01/2004 - "Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia."
|3.||Botulinum Toxins (Botulinum Toxin)
|5.||batrachotoxinin A 20-alpha-benzoate
|8.||Citric Acid (Citrate)
|3.||Nebulizers and Vaporizers (Inhaler)
|5.||Activities of Daily Living (ADL)